Latest News-Dizal (Jiangsu) Pharmaceutical Company Limited Mediaroom_Page

Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

The submission is supported by data from the pivotal WU-KONG1 Part B study, which featured in an or...

2024-11-08 18:01 1101

Sunvozertinib Granted Breakthrough Therapy Designation by China CDE for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Fourth Breakthrough Therapy Designation for sunvozertinib in NSCLC with EGFR exon20ins SHANGHAI, O...

2024-10-13 16:04 2030

Subgroup Analysis from Pivotal WU-KONG1B Study Exhibits Robust Efficacy of Sunvozertinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations Across Different Baseline Characteristics

Results of subgroup analysis from the pivotal WU-KONG1B study in relapsed or refractory NSCLC with ...

2024-09-17 15:47 1847

Golidocitinib Approved in China as First-in-class JAK1 Only Inhibitor for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

* Golidocitinib is a first-in-class Janus kinase 1 (JAK1) only inhibitor approved for the treatme...

2024-06-19 19:30 1967

Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

* Anittumor efficacy of sunvozertinib was observed in patients regardless of baseline EGFR exon20i...

2024-05-24 16:32 1767

Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting

Topline results from Dizal's global pivotal phase II WU-KONG1 Part B study of sunvozertinib will be...

2024-04-24 22:10 1750

FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the First-Line Treatment of Patients with advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

SHANGHAI, April 7, 2024 /PRNewswire/ -- Dizal (688192.SH) today announced that the U.S. Food and Dr...

2024-04-07 19:09 1960

Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine

SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Dizal today announced that the results of a phase 2 pivotal...

2023-12-13 18:00 1663

Dizal Impresses with Its Differentiated Hematological Oncology Portfolio at 2023 ASH

SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- Dizal presented compelling data from its robust portfolio o...

2023-12-12 18:00 1593

Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH

* Full analysis of multinational pivotal study results of golidocitinib in relapsed or refractory...

2023-12-10 18:00 1756

Sunvozertinib Demonstrates Best-in-Class Potential as a First-Line Treatment for EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer Patients

* Sunvozertinib monotherapy demonstrated superior efficacy and excellent safety in patients in th...

2023-10-23 17:34 1353

Golidocitinib Granted Priority Review by China NMPA for the Treatment of r/r PTCL

SHANGHAI, Sept. 21, 2023 /PRNewswire/ -- Dizal announced today that the China National Medical Prod...

2023-09-21 20:26 1595

Dizal Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL

SHANGHAI, Sept. 14, 2023 /PRNewswire/ -- Dizal today announced that the Center for Drug Evaluation ...

2023-09-14 17:07 1545

Dizal Announces Clinical Results of Golidocitinib Published in Annals of Oncology

SHANGHAI, Sept. 10, 2023 /PRNewswire/ -- Dizal today announced the publication of the Phase I clini...

2023-09-10 17:03 1780

Dizal's Sunvozertinib Approved by China NMPA with Potential for Best-in-class Therapy in NSCLC with EGFR Exon20ins Mutations

* Sunvozertinib, a selective EGFR TKI targeting a wide spectrum of EGFR mutations, is the first C...

2023-08-23 19:21 931

2023WCLC Oral Presentation | Molecular Analysis Validates the Effectiveness of Tumor Tissue-Based and Plasma ctDNA Testing in Identifying NSCLC Patients with EGFR Exon20ins Eligible for Treatment with Sunvozertinib

* A high concordance was observed between tumor tissue-based and plasma circulating tumor DNA (ctD...

2023-08-17 17:10 2200

Dizal's Oncology Pipeline Continues to Impress with Two Oral Presentations at 2023 ASCO Annual Meeting

SHANGHAI, May 25, 2023 /PRNewswire/ -- Dizal (688192.SH) today announced that data from its oncolog...

2023-05-26 06:00 2199

Dizal's Rapidly Evolving Oncology Pipeline to Make Waves at 2023 ASCO Meeting

Topline Results from Pivotal Studies of Sunvozertinib and Golidocitinib Selected for Oral Presenta...

2023-04-27 07:20 2056

Dizal Announces China CDE Acceptance of New Drug Application for Sunvozertinib for Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations

SHANGHAI, Jan. 10, 2023 /PRNewswire/ -- Dizal (SHEX: 688192) today announced that the Center for Dr...

2023-01-10 17:03 2238

Dizal Announces Sunvozertinib Meets Primary Endpoint in its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO

* The confirmed objective response (cORR), as assessed by blinded independent central review (BIC...

2022-09-05 22:49 2548